急性心肌梗死后心力衰竭应用冻干重组人脑利钠肽治疗的临床效果及其安全性

Clinical effect and safety of lyophilized recombinant human brain natriuretic peptide in the treatment of heart failure following acute myocardial infarction

目的针对冻干重组人脑利钠肽治疗急性心肌梗死后心力衰竭患者的临床效果及其安全性展开分析与研究。方法选择徐州医科大学附属沭阳医院心内科在2019年2月至2021年2月收治的64例急性心肌梗死后心力衰竭患者作为研究对象,以随机数字表法分为对照组32例、观察组32例,分别使用常规治疗方法以及常规+冻干重组人脑利钠肽治疗,对临床疗效、左心室功能、血清学指标、不良反应发生率进行比较分析。结果观察组临床总有效率、治疗后左室射血分数(LVEF)水平均高于对照组(P<0.05);其治疗后左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、高敏C-反应蛋白(hs-CRP)、B型利钠肽(BNP)水平均低于对照组(P<0.05);不良反应总发生率与对照组比较,差异无统计学意义(P>0.05)。结论对急性心肌梗死后心力衰竭患者使用冻干重组人脑利钠肽治疗的临床效果显著,患者心功能指标改善明显,各项血清指标均有明显降低,且不良反应发生率相对较少,安全性较高,适合推广应用。

Objective To analyze and investigate the clinical effect and safety of lyophilized recombinant human brain natriuretic peptide in the treatment of heart failure following acute myocardial infarction.Methods A total of 64 patients with heart failure following acute myocardial infarction treated in the Department of Cardiology of the Affiliated Shuyang Hospital of Xuzhou Medical University from February 2019 to February 2021 were selected as the research objects.They were divided into 32 cases in the control group and 32 cases in the observation group by the random number table method.They were given routine treatment or routine treatment+lyophilized recombinant human brain natriuretic peptide respectively.The clinical efficacy,left ventricular function,serological indexes and the incidence of adverse reactions were compared and analyzed.Results The total clinical efficacy and post-treatment left ventricular ejection fraction(LVEF)level in the observation group were higher than those in the control group(P<0.05).The post-treatment levels of left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),high-sensitivity C-reactive protein(hs-CRP)and B-type natriuretic peptide(BNP)in the observation group were lower than those in the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of lyophilized recombinant human brain natriuretic peptide in the treatment of heart failure following acute myocardial infarction can significantly enhance the clinical effect,significantly improve the indexes of cardiac function,and significantly reduce various serological indexes,and shows high safety with a relatively low incidence of adverse reactions.It is suitable for popular use.